Aranesp (darbepoetin alfa), the new longer-acting erythropoietin analog for anemia
You'll see patients getting Aranesp (darbepoetin alfa), the new longer-acting erythropoietin analog for anemia.
Aranesp is approved for anemia associated with chronic renal failure...including patients not yet on dialysis.
It's also being studied for anemia due to cancer chemotherapy.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote